The outcomes revealed that CCNA2, TOP2A, AURKA, CCNB2, CDK2, CHEK1, and other potential central targets were therapeutic targets for RR treatment of ESCC. This evidence concerns the gene AURKA and esophageal squamous cell carcinoma.